Elsevier, Cell Genomics, Volume 3, 8 March 2023
Cell type-specific transcriptional differences between brain tissues from donors with Alzheimer's disease (AD) and unaffected controls have been well documented, but few studies have rigorously interrogated the regulatory mechanisms responsible for these alterations. We performed single nucleus multiomics (snRNA-seq plus snATAC-seq) on 105,332 nuclei isolated from cortical tissues from 7 AD and 8 unaffected donors to identify candidate cis-regulatory elements (CREs) involved in AD-associated transcriptional changes.
Elsevier,
Current Developments in Nutrition, Volume 7, March 2023
The authors of this paper conclude that training food service staff and other food service staff may be beneficial to improve meal quality in the Early Care and Education (ECE) programs but point out that positive changes did not last, perhaps indicating a need for longer and rigorous trainings.
Elsevier,
Theriogenology Wild, Volume 2, 2023, 100027
The breeding of captive wild species can play a crucial role in their preservation. One major barrier to successful captive breeding is the difficulty of replicating the natural environment. In this study the authors provide suggestions and recommendations to facilitate future breeding efforts for captive jaguars.
Elsevier,
The Lancet Gastroenterology and Hepatology, Volume 8, March 2023
This Article supports SDG 3 by providing the first systematic review on uptake of testing and treatment and turnaround times to treatment initiation with point-of-care HCV testing versus standard laboratory testing, finding improvements on both fronts; this is reflected in new WHO recommendations on adoption of point-of-care HCV testing as an alternative to laboratory-based tests.
Elsevier,
Annals of Hepatology, Volume 28, 1 March 2023
This article aligns with the SDG goal 3 of Good health and wellbeing and SDG 10 Reduced inequalities by highlighting opportunities to leverage real data to better understand the outcomes of direct-acting antiviral treatment in smaller, discrete subgroups of HCV-infected patients that cannot be comprehensively evaluated in clinical trials.
